Sanofi’s Cholesterol Reducing Drug Continues to be Promising

September 1, 2014 1:52 PM

1 0

In July, French company Sanofi and its U.S. partner, Regeneron, announced that its new cholesterol drug was capable of reducing low-density lipoprotein (LDL) cholesterol, which is often dubbed the bad cholesterol. Now, more details from four of the nine trials revealed that the drug, alirocumab, might be able to cut the number of heart attack and stroke cases.

Alirocumab is an injectable drug that belongs to a new class of medicines called PCSK9 inhibitors, which work by preventing a protein from blocking the body from getting rid of the LDL cholesterol in the bloodstream. The new data came from an interim safety analysis where researchers examined the ef...

Read more

To category page